Edition:
United States

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

674.35INR
4:11am EST
Change (% chg)

Rs-11.70 (-1.71%)
Prev Close
Rs686.05
Open
Rs687.20
Day's High
Rs688.30
Day's Low
Rs665.25
Volume
1,897,606
Avg. Vol
2,030,811
52-wk High
Rs895.00
52-wk Low
Rs582.00

ARBN.NS

Chart for ARBN.NS

About

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system,... (more)

Overall

Beta: 1.08
Market Cap(Mil.): Rs401,455.59
Shares Outstanding(Mil.): 585.17
Dividend: 1.25
Yield (%): 0.47

Financials

  ARBN.NS Industry Sector
P/E (TTM): 17.19 28.39 29.32
EPS (TTM): 39.91 -- --
ROI: -- 13.54 13.03
ROE: -- 14.43 14.17

Aurobindo plans second U.S. plant as Trump calls for local production

MUMBAI Indian drugmaker Aurobindo Pharma plans to set up a factory in the United States for injectable products, it said on Friday, days after U.S. President Donald Trump called on pharmaceutical companies to make more drugs locally.

Feb 10 2017

UPDATE 1-Aurobindo plans second U.S. plant as Trump calls for local production

MUMBAI, Feb 10 Indian drugmaker Aurobindo Pharma plans to set up a factory in the United States for injectable products, it said on Friday, days after U.S. President Donald Trump called on pharmaceutical companies to make more drugs locally.

Feb 10 2017

India's Aurobindo eyes U.S. plant amid Trump push on jobs

MUMBAI, Feb 10 Indian drugmaker Aurobindo Pharma said on Friday it was looking to set up a manufacturing facility for injectable products in the United States, days after President Donald Trump called on pharmaceutical companies to make more drugs locally.

Feb 10 2017

India's Aurobindo shares hit nine-month low on US price-fixing lawsuit

MUMBAI Indian drugmaker Aurobindo Pharma Ltd's shares hit their lowest in more than nine months on Friday after the company was named in a lawsuit alleging it colluded with other drugmakers to fix prices of two commonly used drugs in the United States.

Dec 16 2016

BRIEF-Aurobindo Pharma unit Arrow Generiques to buy select assets in France from Teva

* Aurobindo Pharma Ltd says Arrow Generiques to acquire select assets in France from Teva

Nov 25 2016

BRIEF-India's Aurobindo Pharma Q2 consol net profit rises 33.5 pct

* Sept quarter consol net profit 6.06 billion rupees Source text for Eikon: http://bit.ly/2fS1r1x Further company coverage: (Reporting by Promit Mukherjee)

Nov 14 2016

Founders of India's Aurobindo Pharma to sell up to $135 mln of shares -term sheet

MUMBAI, Oct 6 The founders of India's Aurobindo Pharma are selling shares worth up to $135 million in a block trade on Friday, according to a deal term sheet seen by Reuters.

Oct 06 2016

BRIEF-Aurobindo Pharma gets USFDA tentative approval for Dolutegravir

* Aurobindo Pharma receives USFDA tentative approval for Dolutegravir, allowing the product to be launched in the PEPFAR market Source text: (http://bit.ly/2cTnfIs) Further company coverage: (Bengaluru newsroom)

Sep 22 2016

Indian shares edge up but caution prevails ahead of Fed comments

Aug 24 Indian shares closed slightly higher on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further cues on whether the U.S. Federal Reserve will raise interest rates this year.

Aug 24 2016

Indian shares edge up; caution prevails ahead of Yellen speech

Aug 24 Indian shares crept up on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further clues on whether the Federal Reserve will raise U.S. interest rates this year.

Aug 24 2016

More From Around the Web

Earnings vs. Estimates